For help on how to get the results you want, see our search tips.
1994 results
-
List item
Human medicine European public assessment report (EPAR): Vizarsin (updated)
sildenafil, Erectile Dysfunction
Date of authorisation: 21/09/2009,
, Revision: 18, Authorised, Last updated: 04/07/2022
-
List item
Human medicine European public assessment report (EPAR): Mysildecard (updated)
sildenafil citrate, Hypertension, Pulmonary
Date of authorisation: 15/09/2016,, Revision: 6, Authorised, Last updated: 04/07/2022
-
List item
Human medicine European public assessment report (EPAR): Benlysta (updated)
belimumab, Lupus Erythematosus, Systemic
Date of authorisation: 13/07/2011,
, Revision: 28, Authorised, Last updated: 04/07/2022
-
List item
Human medicine European public assessment report (EPAR): Sildenafil Teva (updated)
sildenafil, Erectile Dysfunction
Date of authorisation: 30/11/2009,, Revision: 17, Authorised, Last updated: 04/07/2022
-
List item
Human medicine European public assessment report (EPAR): Filsuvez (updated)
dry extract from birch bark (DER 5-10 : 1), extraction solvent n-heptane 95% (w/w), Epidermolysis Bullosa Dystrophica; Epidermolysis Bullosa, Junctional
Date of authorisation: 21/06/2022,
, Authorised, Last updated: 04/07/2022
-
List item
Human medicine European public assessment report (EPAR): Uptravi (updated)
Selexipag, Hypertension, Pulmonary
Date of authorisation: 12/05/2016, Revision: 13, Authorised, Last updated: 01/07/2022 -
List item
Human medicine European public assessment report (EPAR): Avastin (updated)
bevacizumab, Carcinoma, Non-Small-Cell Lung; Breast Neoplasms; Ovarian Neoplasms; Colorectal Neoplasms; Carcinoma, Renal Cell
Date of authorisation: 12/01/2005, Revision: 60, Authorised, Last updated: 01/07/2022 -
List item
Human medicine European public assessment report (EPAR): Pregabalin Sandoz (updated)
pregabalin, Anxiety Disorders; Neuralgia; Epilepsy
Date of authorisation: 19/06/2015,, Revision: 13, Authorised, Last updated: 01/07/2022
-
List item
Human medicine European public assessment report (EPAR): Cuprymina (updated)
copper (64Cu) chloride, Radionuclide Imaging
Date of authorisation: 23/08/2012, Revision: 8, Authorised, Last updated: 01/07/2022 -
List item
Human medicine European public assessment report (EPAR): Levetiracetam Actavis (updated)
levetiracetam, Epilepsy
Date of authorisation: 03/10/2011,, Revision: 18, Authorised, Last updated: 01/07/2022
-
List item
Human medicine European public assessment report (EPAR): Pregabalin Sandoz GmbH (updated)
pregabalin, Anxiety Disorders; Epilepsy
Date of authorisation: 19/06/2015,, Revision: 12, Authorised, Last updated: 01/07/2022
-
List item
Human medicine European public assessment report (EPAR): Zostavax (updated)
varicella-zoster virus (live, attenuated), Herpes Zoster; Immunization
Date of authorisation: 19/05/2006, Revision: 33, Authorised, Last updated: 01/07/2022 -
List item
Human medicine European public assessment report (EPAR): COVID-19 Vaccine (inactivated, adjuvanted) Valneva (updated)
SARS-CoV-2 virus (inactivated) Wuhan strain hCoV-19 / Italy / INMI1-isl / 2020, COVID-19 virus infection
Date of authorisation: 24/06/2022,, Authorised, Last updated: 01/07/2022
-
List item
Human medicine European public assessment report (EPAR): Ristfor (updated)
sitagliptin, metformin hydrochloride, Diabetes Mellitus, Type 2
Date of authorisation: 15/03/2010, Revision: 25, Authorised, Last updated: 01/07/2022 -
List item
Human medicine European public assessment report (EPAR): Rydapt (updated)
Midostaurin, Leukemia, Myeloid, Acute; Mastocytosis
Date of authorisation: 18/09/2017,, Revision: 8, Authorised, Last updated: 01/07/2022
-
List item
Human medicine European public assessment report (EPAR): Clopidogrel Taw Pharma (previously Clopidogrel Mylan) (updated)
clopidogrel hydrochloride, Peripheral Vascular Diseases; Stroke; Myocardial Infarction; Acute Coronary Syndrome
Date of authorisation: 21/09/2009,, Revision: 20, Authorised, Last updated: 01/07/2022
-
List item
Human medicine European public assessment report (EPAR): Thalidomide BMS (previously Thalidomide Celgene) (updated)
Thalidomide, Multiple Myeloma
Date of authorisation: 16/04/2008, Revision: 30, Authorised, Last updated: 01/07/2022 -
List item
Human medicine European public assessment report (EPAR): Levetiracetam Actavis Group (updated)
levetiracetam, Epilepsy
Date of authorisation: 04/12/2011,, Revision: 16, Authorised, Last updated: 01/07/2022
-
List item
Human medicine European public assessment report (EPAR): Xermelo (updated)
telotristat etiprate, Carcinoid Tumor; Neuroendocrine Tumors
Date of authorisation: 17/09/2017,, Revision: 13, Authorised, Last updated: 01/07/2022
-
List item
Human medicine European public assessment report (EPAR): Ristaben (updated)
sitagliptin, Diabetes Mellitus, Type 2
Date of authorisation: 15/03/2010, Revision: 24, Authorised, Last updated: 01/07/2022 -
List item
Human medicine European public assessment report (EPAR): Samsca (updated)
Tolvaptan, Inappropriate ADH Syndrome
Date of authorisation: 02/08/2009, Revision: 15, Authorised, Last updated: 01/07/2022 -
List item
Human medicine European public assessment report (EPAR): Inhixa (updated)
enoxaparin sodium, Venous Thromboembolism
Date of authorisation: 15/09/2016,
, Revision: 21, Authorised, Last updated: 01/07/2022
-
List item
Human medicine European public assessment report (EPAR): Caprelsa (updated)
Vandetanib, Thyroid Neoplasms
Date of authorisation: 16/02/2012,, 
, Revision: 22, Authorised, Last updated: 30/06/2022
-
List item
Human medicine European public assessment report (EPAR): Xelevia (updated)
sitagliptin, Diabetes Mellitus, Type 2
Date of authorisation: 21/03/2007, Revision: 34, Authorised, Last updated: 30/06/2022 -
List item
Human medicine European public assessment report (EPAR): Januvia (updated)
sitagliptin, Diabetes Mellitus, Type 2
Date of authorisation: 20/03/2007, Revision: 30, Authorised, Last updated: 30/06/2022